Stay updated on Clinical Trial: Delandistrogene in Duchenne Muscular Dystrophy

Sign up to get notified when there's something new on the Clinical Trial: Delandistrogene in Duchenne Muscular Dystrophy page.
Latest website image capture
Clouds background image

Latest updates to the Clinical Trial: Delandistrogene in Duchenne Muscular Dystrophy page

  1. Check
    5 days ago
    Change Detected
    Summary
    Page revision updated from v3.4.2 to v3.4.3.
    Difference
    0.0%
    Check dated 2026-03-12T02:44:49.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    20 days ago
    Change Detected
    Summary
    Added a 2026 Neurol Ther publication by Audhya et al. on caregiver-reported experiences with Delandistrogene Moxeparvovec in EMBARK and removed the 2025 online-ahead-of-print Neurol Ther article.
    Difference
    0.0%
    Check dated 2026-02-25T21:55:44.000Z thumbnail image
  4. Check
    34 days ago
    Change Detected
    Summary
    Minor site-wide updates were made, including adding revision v3.4.2 and removing notices about funding lapse and revision v3.4.1. These changes do not affect study data, eligibility, or user actions on the page; to avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2026-02-11T16:22:59.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    Added a government funding lapse notice with operating status details and updated the site version to Revision: v3.4.1, removing the previous v3.4.0.
    Difference
    0.3%
    Check dated 2026-02-04T10:45:02.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    These changes are UI/text updates: Show glossary was added; the Last Update Submitted that Met QC Criteria label was introduced; No FEAR Act data capitalization changed; and the revision now displays v3.4.0, with no modifications to core study data, endpoints, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-01-28T06:39:40.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    Added a new publication entry for the EMBARK trial: Mendell JR et al., Two-Year Outcomes Following Delandistrogene Moxeparvovec Treatment in Ambulatory Patients with Duchenne Muscular Dystrophy: Phase 3 EMBARK Trial (Neurol Ther. 2026 Jan 10; online ahead of print). Page revision updated from v3.3.3 to v3.3.4.
    Difference
    0.1%
    Check dated 2026-01-14T02:45:03.000Z thumbnail image

Stay in the know with updates to Clinical Trial: Delandistrogene in Duchenne Muscular Dystrophy

Enter your email address, and we'll notify you when there's something new on the Clinical Trial: Delandistrogene in Duchenne Muscular Dystrophy page.